We are delighted to be collaborating with Flanders Investment and Trade to bring you a half day showcase event on Monday 20 November in Oxford, where we will be spotlighting and catalysing new partnerships between companies working in AI & Machine Learning for Drug Discovery, Diagnostics and Healthcare.
This half-day event, taking place in Oxford will feature:
Showcase presentations from leading Flanders-based and UK life sciences companies utilising AI and Machine Learning for Drug Discovery, Diagnostics and Digital Patient Data.
Opportunity to book private partnering meetings online - these will be via Zoom during the afternoon
Attendance at a networking lunch
Complimentary tickets are available for:
Members of R&D companies who are keen to learn and interact with their European counterparts
Other leaders and decision makers from organisations that provide critical support to the life sciences community both here in the UK and across Europe
9:00 AM - 9:30 AM
Delegate registration and Networking
9:30 AM - 9:45 AM
Introduction and Keynote Presentation: Setting the Scene – the Latest AI & Machine Learning Applications for Drug Discovery, Diagnostics & Healthcare
Dr. Vibhor Gupta is the founder of Pangaea and based in South San Francisco and London. Vibhor trained in oncology and has a breadth of experience in life sciences through his work in industry and academia over the last two decades. Prior to Pangaea, Vibhor started and built the European business for Quantum Secure, which was headquartered in Silicon Valley and was successfully acquired in 2015. Following Quantum Secure, Vibhor served as Senior Vice President of Commercial Strategy and Sales at Seven Bridges Genomics, which was founded at Harvard. Vibhor’s academic career focused on conducting molecular biology studies and building bioinformatics tools and machine learning models with epigenetic, genomic, transcriptomic and clinical trial data in the context of oncology and infectious diseases. Vibhor has access to an extensive global network in the Life sciences industry and is regularly invited to speak at international conferences, government funded programs and investment summits.
Infinitopes is a Cancer Research UK (CRUK) led spinout from Oxford University. We combine world leading expertise in Precision Immunomics antigen discovery, T-cell immunology, biomanufacturing, vaccinology, and oncology clinical trials. Our preclinical vaccines deliver 80% protection, vs control animals dying in three weeks. Lead candidate entering phase I/IIa in 2024.